-transparent.png){kind=logo}
In this prospective follow-up study the prognostic value of the tumor prostacyclin/thromboxane ratio in human breast carcinoma was investigated. The stable degradation products of prostacyclin and thromboxane (6-keto-PGF1 alpha and TXB2, respectively), were measured by radio-immunoassay in homogenized primary tumours from 29 patients with primary non-metastatic breast cancer. The median follow-up was 43 months (range 24-58 months). Patients with recurrent disease or patients who died of breast cancer had a significantly higher 6-keto-PGF1 alpha/TXB2 ratio than the disease-free survivors (p = 0.018 and p = 0.047, respectively). There was no significant difference in the 6-keto-PGF1 alpha and TXB2 levels. These data indicate that the prostacyclin/thromboxane balance in the tumour might be a prognostic factor in breast cancer. Prostanoid may contribute to metastasis in breast cancer, but the problem is complex because the different prostaglandins have numerous actions that may produce both undesirable and desirable effects.
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
December 1990,
The Journal of urology,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
January 1986,
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
October 2001,
Prostaglandins, leukotrienes, and essential fatty acids,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
January 1983,
Acta obstetricia et gynecologica Scandinavica. Supplement,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
February 1982,
Prostaglandins, leukotrienes, and medicine,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
June 1986,
Orvosi hetilap,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
August 1987,
Thrombosis research,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
September 1986,
British journal of cancer,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
May 1978,
Hippokrates,
I B Vergote, and
P A van Dam, and
G M Laekeman, and
G H Keersmaeckers, and
F L Uyttenbroeck, and
A G Herman
November 2002,
Prostaglandins, leukotrienes, and essential fatty acids,
